Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

• Main Authors: Felicia Scaggs Huang (Author), David I. Bernstein (Author), Karen S. Slobod (Author), Allen Portner (Author), Toru Takimoto (Author), Charles J. Russell (Author), Michael Meagher (Author), Bart G. Jones (Author), Robert E. Sealy (Author), Christopher Coleclough (Author), Kristen Branum (Author), Michelle Dickey (Author), Kristen Buschle (Author), Monica McNeal (Author), Mat Makowski (Author), Aya Nakamura (Author), Julia L. Hurwitz (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

SeVRSV is a replication-competent Sendai virus (SeV)-based vaccine carrying the respiratory syncytial virus (RSV) fusion protein (F) gene. Unmanipulated, non-recombinant SeV is a murine parainfluenza virus type 1 (PIV-1) and serves as a Jennerian vaccine for human PIV-1 (hPIV-1). SeV protects Africa...